Search Results - "Mease, Philip"

Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psor by Mease, Philip J.

Get full text

Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment by Mease, Philip J

“…PURPOSE OF REVIEWFibromyalgia is a clinical representation of the neurobiological phenomenon of central sensitization, characterized by chronic widespread…”
Get full text

Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis by Mease, Philip J

“…PURPOSE OF REVIEWIn recent years, there has been an increasing understanding of the importance of the TH17 lineage of T cells and related cytokines, including…”
Get full text

Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis by Mease, Philip

“…Purpose of Review The purpose of this review is to educate the reader about the evolving classification of axial spondyloarthritis (AxSpA) and describe recent…”
Get full text

Navigating the complexity of pain in psoriatic arthritis and axial spondyloarthritis by Mease, Philip J

“…Pain is the most common and often most troublesome feature of chronic autoimmune diseases such as psoriatic arthritis (PsA) and axial spondyloarthritis…”
Get full text

Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy by Mease, Philip J.

“…Spondyloarthritis is a common rheumatologic disease, present in up to 2% of the population, characterized by inflammatory arthritis, often with enthesitis,…”
Get full text

Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis by Mease, Philip J., Armstrong, April W.

“…Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease. Up to 40 % of patients with psoriasis will go on to develop PsA, usually within…”
Get full text

2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria by Wolfe, Frederick, Clauw, Daniel J, Fitzcharles, Mary-Ann, Goldenberg, Don L, Häuser, Winfried, Katz, Robert L, Mease, Philip J, Russell, Anthony S, Russell, I. Jon, Walitt, Brian

“…Abstract Objectives The provisional criteria of the American College of Rheumatology (ACR) 2010 and the 2011 self-report modification for survey and clinical…”
Get full text

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial by Mease, Philip J., Gladman, Dafna D., Collier, David H., Ritchlin, Christopher T., Helliwell, Philip S., Liu, Lyrica, Kricorian, Gregory, Chung, James B.

“…Objective To examine the efficacy of methotrexate monotherapy relative to etanercept monotherapy and the value of combining methotrexate and etanercept for the…”
Get full text

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials by Mease, Philip J, Helliwell, Philip S, Hjuler, Kasper Fjellhaugen, Raymond, Kyle, McInnes, Iain

“…To compare the efficacy and safety of brodalumab, an interleukin-17 receptor subunit A inhibitor, with placebo, in patients with psoriatic arthritis (PsA)…”
Get more information

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial by McInnes, Iain B, Prof, Mease, Philip J, Prof, Kirkham, Bruce, MD, Kavanaugh, Arthur, Prof, Ritchlin, Christopher T, Prof, Rahman, Proton, Prof, van der Heijde, Désirée, Prof, Landewé, Robert, Prof, Conaghan, Philip G, Prof, Gottlieb, Alice B, Prof, Richards, Hanno, MD, Pricop, Luminita, MD, Ligozio, Gregory, MSc, Patekar, Manmath, MD, Mpofu, Shephard, MD

“…Summary Background Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis of psoriatic arthritis. We assessed the efficacy and…”
Get full text

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial by Mease, Philip J, Rahman, Proton, Gottlieb, Alice B, Kollmeier, Alexa P, Hsia, Elizabeth C, Xu, Xie L, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Zhuang, Yanli, van der Heijde, Désirée, McInnes, Iain B

“…The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds…”
Get full text

New treatments for PsA meet targeted therapy goals by Mease, Philip J.

“…Interest in therapies for psoriatic arthritis (PsA) has increased in response to recognition that many patients remain undiagnosed and are inadequately…”
Get full text

Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy by Mease, Philip J.

“…Spondyloarthritis is a common rheumatologic disease, present in up to 2% of the population, characterized by inflammatory arthritis, often with enthesitis,…”
Get full text

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis by Coates, Laura C., Kavanaugh, Arthur, Mease, Philip J., Soriano, Enrique R., Laura Acosta‐Felquer, Maria, Armstrong, April W., Bautista‐Molano, Wilson, Boehncke, Wolf‐Henning, Campbell, Willemina, Cauli, Alberto, Espinoza, Luis R., FitzGerald, Oliver, Gladman, Dafna D., Gottlieb, Alice, Helliwell, Philip S., Husni, M. Elaine, Love, Thorvardur J., Lubrano, Ennio, McHugh, Neil, Nash, Peter, Ogdie, Alexis, Orbai, Ana‐Maria, Parkinson, Andrew, O'Sullivan, Denis, Rosen, Cheryl F., Schwartzman, Sergio, Siegel, Evan L., Toloza, Sergio, Tuong, William, Ritchlin, Christopher T.

“…Objective To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of…”
Get full text

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial by McInnes, Iain B, Behrens, Frank, Mease, Philip J, Kavanaugh, Arthur, Ritchlin, Christopher, Nash, Peter, Masmitja, Jordi Gratacós, Goupille, Philippe, Korotaeva, Tatiana, Gottlieb, Alice B, Martin, Ruvie, Ding, Kevin, Pellet, Pascale, Mpofu, Shephard, Pricop, Luminita

“…Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision making. The EXCEED study evaluated the efficacy and safety of secukinumab…”
Get full text

Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review by Mease, Philip, Deodhar, Atul

“…Optimal treatment of nonradiographic axial spondyloarthritis depends on accurate and timely diagnosis of the underlying disease; however, patients present with…”
Get full text

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) by Nash, Peter, Mease, Philip J, McInnes, Iain B, Rahman, Proton, Ritchlin, Christopher T, Blanco, Ricardo, Dokoupilova, Eva, Andersson, Mats, Kajekar, Radhika, Mpofu, Shephard, Pricop, Luminita

“…The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in…”
Get full text

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis by Mease, Philip J, Gottlieb, Alice B, van der Heijde, Désirée, FitzGerald, Oliver, Johnsen, Alyssa, Nys, Marleen, Banerjee, Subhashis, Gladman, Dafna D

“…To assess the efficacy and safety of abatacept, a selective T-cell costimulation modulator, in a phase III study in psoriatic arthritis (PsA). This study…”
Get more information

The Efficacy and Safety of Clazakizumab, an Anti–Interleukin‐6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis by Mease, Philip J., Gottlieb, Alice B., Berman, Alberto, Drescher, Edit, Xing, Jun, Wong, Robert, Banerjee, Subhashis

“…Objective To evaluate the efficacy of clazakizumab, a monoclonal antibody with high affinity and specificity for the interleukin‐6 (IL‐6) cytokine, in…”
Get full text